Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Protagonist Therapeutics, Inc.”

32 pharma patents match "Protagonist Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 32
Index total 30,257
Page 1 / 2

Quick answer

This filtered view shows 32 pharmaceutical patents matching "Protagonist Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

32 results for “Protagonist Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 12269856

    Hepcidin analogues and uses thereof

    Protagonist Therapeutics, Inc. · Granted Apr 8, 2025 · Expires Apr 3, 2045

    granted
  2. US 12234300

    Conjugated hepcidin mimetics

    Protagonist Therapeutics, Inc. · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted
  3. US 12018057

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Protagonist Therapeutics, Inc. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  4. US 11939361

    Compositions of peptide inhibitors of Interleukin-23 receptor

    Protagonist Therapeutics, Inc. · Granted Mar 26, 2024 · Expires Mar 21, 2044

    granted
  5. US 11884748

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Protagonist Therapeutics, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  6. US 11845808

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Protagonist Therapeutics, Inc. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  7. US 11840581

    α4β7 thioether peptide dimer antagonists

    Protagonist Therapeutics, Inc. · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  8. US 11807674

    Hepcidin analogues and uses thereof

    Protagonist Therapeutics, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  9. US 11753443

    Conjugated hepcidin mimetics

    Protagonist Therapeutics, Inc. · Granted Sep 12, 2023 · Expires Sep 7, 2043

    granted
  10. US 11472842

    Analogues of hepcidin mimetics with improved in vivo half lives

    Protagonist Therapeutics, Inc. · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted
  11. US 11111272

    α4α7 peptide monomer and dimer antagonists

    Protagonist Therapeutics, Inc. · Granted Sep 7, 2021 · Expires Sep 2, 2041

    granted
  12. US 11041000

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Protagonist Therapeutics, Inc. · Granted Jun 22, 2021 · Expires Jun 17, 2041

    granted
  13. US 10941183

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Protagonist Therapeutics, Inc. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  14. US 10787490

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Protagonist Therapeutics, Inc. · Granted Sep 29, 2020 · Expires Sep 24, 2040

    granted
  15. US 10729676

    Opioid agonist peptides and uses thereof

    Protagonist Therapeutics, Inc. · Granted Aug 4, 2020 · Expires Jul 30, 2040

    granted
  16. US 10626146

    α4β7 thioether peptide dimer antagonists

    Protagonist Therapeutics, Inc. · Granted Apr 21, 2020 · Expires Apr 16, 2040

    granted
  17. US 10501515

    Hepcidin analogues and uses thereof

    Protagonist Therapeutics, Inc. · Granted Dec 10, 2019 · Expires Dec 5, 2039

    granted
  18. US 10442846

    Hepcidin analogues and uses thereof

    Protagonist Therapeutics, Inc. · Granted Oct 15, 2019 · Expires Oct 10, 2039

    granted
  19. US 10407468

    Methods for synthesizing α4β7 peptide antagonists

    Protagonist Therapeutics, Inc. · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  20. US 10301371

    Cyclic monomer and dimer peptides having integrin antagonist activity

    Protagonist Therapeutics, Inc. · Granted May 28, 2019 · Expires May 23, 2039

    granted
  21. US 10278957

    Opioid agonist peptides and uses thereof

    Protagonist Therapeutics, Inc. · Granted May 7, 2019 · Expires May 2, 2039

    granted
  22. US 10196424

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Protagonist Therapeutics, Inc. · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted
  23. US 10059744

    α4β7 thioether peptide dimer antagonists

    Protagonist Therapeutics, Inc. · Granted Aug 28, 2018 · Expires Aug 23, 2038

    granted
  24. US 10035824

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Protagonist Therapeutics, Inc. · Granted Jul 31, 2018 · Expires Jul 26, 2038

    granted